Dalai Sibasankar, Limaye Uday S, Maturu Mohan V Sumedha, Kolli Satya Rao, Pati Rajesh, Marthati Madhusudhana Babu, Modi Sailesh, Datla Aravind Varma, Anantamakula Sameera, Donkada Rajasekhar
Interventional Neuroradiology, Medicover Hospitals, Visakhapatnam, IND.
Interventional Neuroradiology, Lilavati Hospital, Mumbai, IND.
Cureus. 2022 Sep 19;14(9):e29311. doi: 10.7759/cureus.29311. eCollection 2022 Sep.
Background Aneurysmal Subarachnoid Haemorrhage (aSAH) is a complex and critical neurological condition associated with significant mortality and morbidity. Apart from the initial insult due to the aneurysmal rupture itself, re-bleeding and severe cerebral vasospasm are some of the complications of aSAH that result in overall poor outcomes. Cerebral vasospasm in post-aSAH can result in delayed ischaemic neurological deficits. In the absence of timely interventions, it can lead to grave consequences for the patient. Management of cerebral vasospasm has been evolving over the years to prevent mortality and morbidity in aSAH patients. Materials and methods During 36 months from January 2018 to December 2020, 164 patients were admitted with aSAH in multiple Indian centres. Endovascular methods were used to treat all the aneurysms. Patients were observed for clinically symptomatic cerebral vasospasm. Patients with suspected vasospasm were further evaluated with a transcranial Doppler (TCD), brain computed tomography (CT) or magnetic resonance imaging (MRI) scan. In addition, digital subtraction angiography (DSA) of cerebral vessels was performed to evaluate vasospasm further. Twenty-two patients had clinically and angiographically significant vasospasm, and 20 patients were treated with transluminal balloon angioplasty (TBA). Results Satisfactory lumen dilation was achieved in 79 out of the 91 (86.81%) vasospastic segments, namely, distal internal carotid arteries (ICAs) 100%; middle cerebral arteries (MCA) 97.56% (M1=100%, M2=100%, M3=87.5%); vertebral arteries-100%; basilar arteries-100%; anterior cerebral arteries (ACA) 67.64% (A1=75%, A2=57.14%). The mean Modified Rankin Scale (mRS) score at 90 days was 0.75. 17 patients (85%) had an overall good outcome with no new neurological deficits. There were no cases of vessel rupture, dissection or thromboembolic complications. Conclusion TBA is a valuable, safe and effective option for managing clinically significant vasospasm caused by aSAH, adjuvant to medical management.
动脉瘤性蛛网膜下腔出血(aSAH)是一种复杂且严重的神经系统疾病,具有较高的死亡率和发病率。除了动脉瘤破裂本身造成的初始损伤外,再出血和严重的脑血管痉挛是aSAH的一些并发症,会导致总体预后不良。aSAH后的脑血管痉挛可导致延迟性缺血性神经功能缺损。若不及时干预,会给患者带来严重后果。多年来,脑血管痉挛的治疗方法不断发展,以预防aSAH患者的死亡率和发病率。
在2018年1月至2020年12月的36个月期间,印度多个中心收治了164例aSAH患者。采用血管内方法治疗所有动脉瘤。观察患者是否出现临床症状性脑血管痉挛。对疑似血管痉挛的患者进一步进行经颅多普勒(TCD)、脑部计算机断层扫描(CT)或磁共振成像(MRI)扫描评估。此外,进行脑血管数字减影血管造影(DSA)以进一步评估血管痉挛。22例患者出现临床和血管造影学上显著的血管痉挛,20例患者接受了经腔球囊血管成形术(TBA)治疗。
91个血管痉挛节段中的79个(86.81%)实现了满意的管腔扩张,即颈内动脉(ICA)远端100%;大脑中动脉(MCA)97.56%(M1 = 100%,M2 = 100%,M3 = 87.5%);椎动脉100%;基底动脉100%;大脑前动脉(ACA)67.64%(A1 = 75%,A2 = 57.14%)。90天时改良Rankin量表(mRS)平均评分为0.75。17例患者(85%)总体预后良好,无新的神经功能缺损。未发生血管破裂、夹层或血栓栓塞并发症。
TBA是治疗aSAH所致临床显著血管痉挛的一种有价值、安全且有效的选择,可作为药物治疗的辅助手段。